The benefit of this combinatorial treatment in NSCLC showing KRAS mutation and high c-MYC expression was supported by the differential efficacy in four PDX cell lines decreasing the viability to up to 50%. This evidence concerns the gene KRAS and non-small cell lung carcinoma.